

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Tuesday 31 January 2017, 10.00am – 2.10 pm

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

| | | |
|-----------------|----------------------------------|-----------------------|
| Present: | 1. Professor Gary McVeigh, Chair | Present for all notes |
| | 2. Dr Lindsay Smith, Vice Chair | Present for all notes |
| | 3. Dr Graham Ash | Present for all notes |
| | 4. Dr Andrew Black | Present for all notes |
| | 5. Dr Matthew Bradley | Present for all notes |
| | 6. David Chandler | Present for all notes |
| | 7. Dr Ian Davidson | Present for all notes |
| | 8. Professor Simon Dixon | Present for all notes |
| | 9. Gillian Ells | Present for all notes |
| | 10. Professor Rachel Elliott | Present for all notes |
| | 11. Professor Paula Ghaneh | Present for all notes |
| | 12. Dr Susan Griffin | Present for all notes |
| | 13. Professor David Meads | Present for all notes |
| | 14. Dr Malcolm Oswald | Present for all notes |
| | 15. Dr Brian Shine | Present for all notes |

In attendance:

| | | |
|-----------------------|--|----------------------------|
| Prof Adrian Bagust | Evidence Review Group representative, Liverpool Reviews and Implementation Group | Present for notes 18 to 26 |
| Dr Paul Cane | Consultant Histopathologist, Clinical Expert, nominated by the Royal College of Pathologists | Present for notes 5 to 13 |
| Professor Peter Clark | CDF Clinical Lead, NHS England | Present for notes 5 to 17 |
| Carol Davies | Patient expert, nominated by the National Lung Cancer Forum for Nurses | Present for notes 5 to 15 |
| Nigel Fleeman | Evidence Review Group representative, Liverpool Reviews and Implementation Group | Present for notes 18 to 26 |

| | | |
|------------------------------|--|----------------------------|
| Dr Martin Forster | Consultant in Medical Oncology, Clinical Expert, nominated by NCRI-RCP-RCR-ACP | Present for notes 5 to 13 |
| Dr Jesme Fox | Patient Expert, nominated by the Roy Castle Lung Cancer Foundation | Present for notes 5 to 15 |
| Dr Janette Greenhalgh | Evidence Review Group representative, Liverpool Reviews and Implementation Group | Present for notes 5 to 15 |
| Marcela Haasova | Technical Analyst, National Institute for Health and Care Excellence | Present for notes 1 to 17 |
| Helen Knight | Associate Director, National Institute for Health and Care Excellence | Present for all notes |
| Fay McCracken | Technical Adviser, National Institute for Health and Care Excellence | Present for notes 1 to 17 |
| James Mahon | Evidence Review Group representative, Liverpool Reviews and Implementation Group | Present for notes 5 to 15 |
| Kate Moore | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Alex Sexton | Administrator, National Institute for Health and Care Excellence | Present for all notes |
| Helen Tucker | Technical Analyst National Institute for Health and Care Excellence | Present for notes 18 to 29 |
| Non-public observers: | | |
| Richard Barrett | Administrator, National Institute for Health and Care Excellence | Present for notes 1 to 17 |

| | | |
|------------------|---|---------------------------|
| John Borrill | Technical Adviser, Scientific Advice, National Institute for Health and Care Excellence | Present for notes 1 to 17 |
| Ann Greenwood | Senior Medical Editor, National Institute for Health and Care Excellence | Present for all notes |
| Lydia Shears | Public Involvement Adviser, National Institute for Health and Care Excellence | Present for 1 to 17 |
| Maroulla Whitely | Business Analyst, National Institute for Health and Care Excellence | Present for all notes |

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer, and pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
2. The Chair welcomed Professor Rachel Elliott to her first meeting as a member of Appraisal Committee D and thanked Dr Graham Ash, David Chandler and Dr Brian Shine (who are members of other Technology Appraisal Committees) for participating in the meeting.
3. Apologies were received from Dr Aomesh Bhatt, Professor David Bowen, Susan Dutton, Sumithra Maheswaran, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu.

Any other Business

4. None

Appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer

Part 1 – Open session

5. The Vice Chair welcomed the invited experts, Dr Paul Cane, Professor Peter Clark, Carol Davies, Dr Martin Forster, Dr Jesme Fox, Dr Janette Greenhalgh, and James Mahon, to the meeting and they introduced themselves to the committee.
6. The Vice Chair welcomed company representatives from Merck Sharp and Dohme to the meeting.
7. The Vice Chair asked all Committee members to declare any relevant interests:

- 7.1. Dr Graham Ash, Dr Andrew Black, Dr Matthew Bradley, David Chandler, Dr Ian Davidson, Professor Simon Dixon, Gillian Ells, Professor Rachel Elliott, Professor Paula Ghaneh, Dr Susan Griffin, Professor Gary McVeigh, Professor David Meads, Malcolm Oswald, Dr Brian Shine and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer
8. The Vice Chair asked all NICE Staff to declare any relevant interests.
- 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer.
9. The Vice Chair asked all other invited guests to declare their relevant interests.
- 9.1. Professor Peter Clark declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer.
- 9.2. Dr Paul Cane declared a personal non-specific financial interest as he had received lecture speaker fees from Merck Sharp and Dohme in the past 12 months.
9. 2.1 It was agreed that this declaration would not prevent Dr Paul Cane from participating in this section of the meeting.
- 9.3. Carol Davies declared a personal and non-personal non-specific financial interest as she and the National Lung Cancer Forum had received pharmaceutical and law firm funding for conferences in the past 12 months.
9. 3.1 It was agreed that this declaration would not prevent Carol Davies from participating in this section of the meeting.
- 9.4. Dr Martin Forster declared a personal non-specific financial interest as he had received sponsorship from Merck Sharp and Dohme and other pharmaceutical companies to attend conferences in the past 12 months.
9. 4.1 It was agreed that this declaration would not prevent Dr Martin Forster from participating in this section of the meeting.

- 9.5. Dr Jesme Fox declared a non-personal non-specific financial interest as the Roy Castle Lung Cancer Foundation had received funding from a number of pharmaceutical companies, including from Merck Sharp and Dohme, in the past 12 months.
9. 5.1 It was agreed that this declaration would not prevent Dr Jesme Fox from participating in this section of the meeting.
10. The Vice Chair introduced the lead team, Dr Andrew Black and Malcolm Oswald, who gave presentations on the clinical effectiveness of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer; the Vice Chair then gave a presentation on the cost-effectiveness.
11. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy
12. The Vice Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. The information was supplied by the company.
14. The Vice-Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal. The company representatives, experts and Evidence Review Group representatives left the meeting.
15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for untreated PD-L1 positive metastatic non-small-cell lung cancer.
- 15.1. The committee decision was based on consensus.
16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine

Part 1 – Open session

17. The Chair welcomed invited experts, Professor Adrian Bagust and Nigel Fleeman, to the meeting and they introduced themselves to the committee.
18. The Chair welcomed company representatives from Shire Pharmaceuticals Ltd to the meeting.
19. The Chair asked all Committee members to declare any relevant interests

- 19.1. Dr Graham Ash, Dr Andrew Black, Dr Matthew Bradley, David Chandler, Dr Ian Davidson, Gillian Ells, Professor Rachel Elliott, Professor Paula Ghaneh, Dr Susan Griffin, Professor Gary McVeigh, Professor David Meads, Malcolm Oswald, Dr Brian Shine and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
- 19.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken research for comparator companies on unrelated topics.
 - 19.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
20. The Chair asked all NICE Staff to declare any relevant interests.
 - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
21. The Chair asked all other invited guests to declare their relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
22. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
25. The Chair then thanked the company representatives and Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued.
27. The Committee continued to discuss the clinical and cost effectiveness of pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine.
 - 27.1. The committee decision was based on consensus.
28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Documentation [FAD] in line with their decisions.

Date, time and venue of the next meeting

29. Tuesday 28 February 2017, from 10am – 5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.